Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP1CA | P62136 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MARS1 | P56192 | 2/20 | 0.53 |
| ▸ | RPA1 | P27694 | 7/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.51 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.51 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.50 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.50 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | FABP3 | P05413 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764874 | 0.96 | PPP1CA (0.61) | PPP1CAL3MBTL1MARS1RPA1MDM2 | |
| SCHEMBL1765079 | 0.91 | PPP1CA (0.60) | PPP1CAL3MBTL1MARS1RPA1MDM2 | |
| SCHEMBL1765293 | 0.87 | MDM2 (0.68) | PPP1CAL3MBTL1MARS1RPA1MDM2 | |
| SCHEMBL1764923 | 0.87 | FAAH (0.56) | PPP1CASLC16A3SLC16A1MCTS1FAAH | |
| SCHEMBL1764960 | 0.86 | HRH3 (0.56) | PPP1CANSD2NSD1NSD3LPAR5 | |
| SCHEMBL1765024 | 0.85 | PPP1CA (0.68) | PPP1CAL3MBTL1MARS1RPA1SLC16A3 | |
| SCHEMBL3431206 | 0.85 | SLC16A3 (0.49) | PPP1CASLC16A3SLC16A1MCTS1FAAH | |
| SCHEMBL1765063 | 0.85 | PPP1CA (0.82) | PPP1CAL3MBTL1MARS1RPA1SMN1; SMN2 | |
| SCHEMBL1110689 | 0.83 | PPP1CA (0.64) | PPP1CAL3MBTL1MARS1RPA1SLC16A3 | |
| SCHEMBL1110855 | 0.82 | PPP1CA (0.87) | PPP1CAL3MBTL1MARS1RPA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| EP-2254885-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AiCuris GmbH & Co. KG (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009115213-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115213-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | TPMT, PAICS, THPO | PPP1CA 1664/4885L3MBTL1 1446/4885MARS1 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.